Trial Profile

A Randomised Phase III Open Label Study of Regorafenib + Nivolumab vs Standard Chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Regorafenib (Primary) ; Docetaxel; Irinotecan; Paclitaxel; Tipiracil/trifluridine
Indications Adenocarcinoma; Carcinoma; Gastric cancer; Oesophageal cancer
Focus Therapeutic Use
Acronyms INTEGRATEIIb

Most Recent Events

10 Jun 2026 The protocol has been amended to change in primary endpoint time frame.
10 Jun 2026 Actual primary completion date changed from 9 Jul 2025 to 14 Jan 2025.
10 Jun 2026 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com